Tempus Labs (TEM) - Long-Term Debt to Capital

Symbol and logo of brand Tempus AI, Inc. (TEM)

Tempus AI, Inc (TEM) dominates precision therapy through unique AI insights and premium pricing, bolstered by a massive barrier to entry due to exclusive genomic databases and stringent FDA oversight. This chart on GURU.Markets for the separate_debt_long_eq metric reflects 3.14. The company's success is based on the synergy between top oncologists and developers united by the ambitious goal of defeating cancer.

Tempus AI, Inc. (TEM): Long-Term Debt to Capital from 06/15/2024 to 10/28/2026

Summary analytical data breakdowns for Tempus AI, Inc. (TEM)

- price and consensus price forecast:
Share Price Tempus|TEM - Analyst Consensus Forecast
- market capitalization data:
Market Capitalization Tempus AI|TEM - Real Price to Acquire Entire Company
- book capitalization data:
Book Price of a Share Tempus|TEM - Book Capitalization|Market-to-Book Ratio tempus.com|TEM - Aggregate Company Assets
- debt and liquidity data:
Total Debt to Equity Ratio Tempus AI, Inc|TEM - Long-Term Debt to Equity|Current Liabilities to Equity Tempus AI Inc|TEM - Company Total Debt|Debts to Book Capitalization Tempus AI|TEM - Company Long-Term Debt|Short-Term Debt Volume Tempus
Summary company analysis:Tempus AI, Inc
Brand item of Tempus

Tempus AI, Inc (TEM) is rapidly scaling the implementation of AI-driven genomic analysis in oncology, which requires significant capital expenditures. By analyzing the long-term debt-to-equity ratio, an investor assesses the proportion of liabilities with a maturity of over one year relative to equity, where a decrease in leverage signals financial stability, while an increase indicates the use of borrowed capital to accelerate expansion.

Direct competitors

Long-Term Debt to Capital Ratio Qiagen NV|Long-Term Debt to Capital IONS|Long-Term Debt to Capital Repligen Inc. RGEN|Long-Term Debt to Equity Ratio Avidity Biosciences (RNA)|Long-Term Loans to Capital Ratio crisprtx.com CRSP|WGS (GeneDx) - Long-Term Debt to Capital|RARE: Long-Term Liabilities to Capital|BEAM (Beam Therapeutics Corp) - Long-Term Debt to Equity|SRPT (Sarepta Corp) - Long-Term Debt to Equity Ratio|Long-Term Debt to Equity Twist Bioscience TWST|Long-Term Liabilities to Equity 10xgenomics.com (TXG)|Long-Term Debt to Equity Ratio NTLA|Long-Term Debt to Capital STOK (Stoke Therapeutics Inc)|Long-Term Debt to Equity BLFS|WVE - Ratio of Long-Term Indebtedness to Capital|Long-Term Debt to Equity Ratio Maze Therapeutics Inc (MAZE)|SION - Long-Term Debt to Capital Coefficient|PRME: Long-Term Debt to Capital|Taysha Gene Therapies Inc (TSHA) - Long-Term Debt to Capital|QURE: Long-Term Debt to Capital|Ratio of Long-Term Indebtedness to Capital MeiraGTx Corp (MGTX)|REGENXBIO Inc. (RGNX) - Long-Term Debt to Equity Ratio|Long-Term Debt to Capital Coefficient solidbio.com (SLDB)|Long-Term Debt to Capital OCGN|Pacific Biosciences of California, Inc. - Ratio of Long-Term Indebtedness to Capital|Benitec (BNTC) - Long-Term Debt to Equity|DSGN - Long-Term Debt to Capital Ratio|RCKT (Rocket Pharmaceuticals) - Long-Term Debt to Capital|Long-Term Debt to Equity Ratio 4dmoleculartherapeutics.com|Lexeo Therapeutics Inc. (LXEO) - Long-Term Debt to Equity Ratio|Long-Term Loans to Capital Ratio Korro Bio, Inc|Editas - Long-Term Debt to Capital|Long-Term Liabilities to Capital SLN (Silence Therapeutics Corp)|ProQR Therapeutics - Long-Term Debt to Equity|Long-Term Debt to Equity Ratio Codexis Inc CDXS|Sangamo Therapeutics, Inc. (SGMO) - Long-Term Debt to Capital|NAUT: Long-Term Debt to Capital Ratio|Long-Term Debt to Equity Metagenomi, Inc|Precision BioSciences Inc. (DTIL) - Long-Term Debt to Capital Ratio|GBIO (Generation Bio Co) - Long-Term Debt to Capital|Long-Term Debt to Capital boundlessbio.com (BOLD)|Long-Term Debt to Equity Ratio Exicure, Inc.|Long-Term Loans to Capital Ratio imunon.com (IMNN)|PHIO: Long-Term Debt to Capital|Mustang Bio Inc - Long-Term Liabilities to Capital|RNAZ: Long-Term Debt to Equity|BNGO: Long-Term Debt to Equity Ratio|Long-Term Debt to Equity Applied DNA Sciences, Inc. (APDN)|Long-Term Liabilities to Equity bluebird bio Inc.|IPA (ImmunoPrecise Antibodies Ltd) - Long-Term Debt to Equity Ratio|Long-Term Debt to Capital OMGA|OMIC (Singular Genomics Systems) - Long-Term Debt to Equity|Ratio of Long-Term Indebtedness to Capital regulusrx.com RGLS|Long-Term Debt to Equity Ratio Syros Pharmaceuticals, Inc.|Long-Term Debt to Capital Coefficient Telesis Bio Inc. TBIO|TRACON - Long-Term Debt to Capital|UBX - Long-Term Debt to Capital